Renal Cell Carcinoma Recurrent
3 clinical trials · Condition
◉ Watch Renal Cell Carcinoma Recurrent
| Record | Firm | Date |
|---|---|---|
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) (NCT03634540) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2018-09-27 |
| A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) (NCT02974738) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2016-12-07 |
| Study of the Combination of CM082 With Everolimus in Patients With mRCC (NCT02577458) | AnewPharma | 2015-09-01 |
Track Renal Cell Carcinoma Recurrent automatically
Every clearance here is in the API, with alerts when new ones post.